Biotech Values

[DewDiligence]

Does Bavarian Nordic’s Prostvac work in CRPC? Possibly (but hard to tell based on these data):

http://in.reuters.com/article/2015/02/24/us-bavarian-nordic-cancer-idINKBN0LS2CI20150224

Patients were treated with the company's Prostvac vaccine, in addition to escalating doses of Bristol-Myers Squibb Co's Yervoy… On average, patients taking both drugs survived 31.3 months, compared with a predicted survival period of 18.5 months that had been based on historical survival data for older chemotherapy treatments.

Among the 15 patients who received the highest 10 milligram dose of Yervoy in combination with Prostvac, 20 percent remained alive at 80 months. Data from the combination trial were especially impressive, considering that Yervoy had previously failed in Bristol-Myers' own trials to prolong survival in patients with advanced prostate cancer.

Complete data from the Prostvac study are slated to be presented on Thursday at the Genitourinary Cancers Symposium in Orlando.